Semaglutide
GLP-1 receptor agonist. Ozempic (injection) / Wegovy (weight loss) / Rybelsus (oral). Used in bodybuilding for appetite suppression and fat loss during cutting phases.
Overview
GLP-1 receptor agonist. Ozempic (injection) / Wegovy (weight loss) / Rybelsus (oral). Used in bodybuilding for appetite suppression and fat loss during cutting phases.
May mildly affect liver enzymes (typically improvement with fat loss), significant appetite suppression, improves fasting glucose and HbA1c, improves lipid profile (lower triglycerides, LDL), can cause mild elevations in amylase/lipase (monitor for pancreatitis), reduces CRP (anti-inflammatory)
Compound Guide
Structure: Acylated GLP-1 analog with 94% homology to native GLP-1. Albumin binding extends half-life to weekly dosing.
Dosage:
- Weight loss (titrate up): 0.25mg/week x4 weeks → 0.5mg/week x4 weeks → 1.0mg/week x4 weeks → 1.7mg/week → 2.4mg/week
- Bodybuilding cut: Most use 0.5-1.0mg/week (lower doses often sufficient for appetite control)
- Oral (Rybelsus): 3mg/day → 7mg/day → 14mg/day
Administration:
- SubQ injection once weekly, abdomen/thigh/upper arm, rotate sites
- Oral form must be taken on empty stomach with <120mL water, 30 min before food
- Titrate slowly to minimise GI side effects
Key Notes:
- Extremely effective appetite suppressant — the primary benefit for bodybuilders during cuts
- GI side effects (nausea, vomiting, diarrhoea) are common during titration — start low
- Risk of muscle loss during aggressive caloric deficit — must maintain high protein intake and resistance training
- Improves metabolic markers: HbA1c, fasting glucose, triglycerides, LDL, CRP
- Small risk of pancreatitis — monitor amylase/lipase if abdominal pain occurs
- Can slow gastric emptying significantly — relevant for pre-anaesthesia considerations
- May reduce effectiveness of oral medications (delayed absorption)
- Monitor: fasting glucose, HbA1c, lipid panel, amylase/lipase, liver enzymes
Usage History
Marker Interactions
Frequently Asked Questions
Related Articles
Does 5-Amino-1MQ Actually Burn Fat? (No Human Trials Yet)
5-amino-1MQ is an NNMT inhibitor sold for fat loss and NAD+. Here's the real evidence, honest dosing, and the bloodwork to run on it.
Does Your DNA Decide How You Metabolize Steroids and Meds?
Use your 23andMe raw data to read how you metabolize steroids, tamoxifen, statins and GLP-1 drugs. Free, in-browser, nothing uploaded.
How Tesamorelin Cuts Visceral Fat Without Raising Blood Sugar
Tesamorelin cuts visceral fat 15-18% in 26 weeks while keeping glucose neutral. Bloodwork protocol, decision tree, and how it compares to CJC and MK-677.
How Much Muscle You Lose Cutting on Retatrutide
TRIUMPH-1 showed 28.3% weight loss. Here's how much was muscle, what DEXA data predicts for athletes, and how to preserve muscle on a retatrutide cut.
Quick Reference
Category
GLP-1
Half-Life
7 days
Detection Time
N/A